CD274 and cervical cancer: A recent study reported on a PROTAC stapledpeptide specifically targeting ZDHHC3, a palmitoyltransferase thatregulates PD-L1 stability.92 This stapledpeptide PROTAC (SP-PROTAC) was more effective than BMS-8, a PD-L1inhibitor, in reducing PD-L1 levels and enhancing cytokine productionand T-cell activation in human cervical cancer cells.93 Further, this study showed how SP-PROTACs can act as noveldual agents that both inhibit and degrade PD-L1.